{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:28:12Z","timestamp":1792182492059,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":1138,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpsmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pain and Symptom Management"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.jpainsymman.2016.05.032","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T01:50:21Z","timestamp":1475632221000},"page":"901-919.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Somatostatin Analogues Compared With Placebo and Other Pharmacologic Agents in the Management of Symptoms of Inoperable Malignant Bowel Obstruction: A Systematic Review"],"prefix":"10.1016","volume":"52","author":[{"given":"George P.","family":"Obita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine G.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Currow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpainsymman.2016.05.032_bib1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/CMAR.S29297","article-title":"Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution","volume":"4","author":"Tuca","year":"2012","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib2","series-title":"Oxford textbook of palliative medicine","first-page":"496","article-title":"Pathophysiology and management of malignant bowel obstruction","author":"Ripamonti","year":"2005"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib3","first-page":"259","article-title":"Medical management of intestinal obstruction in terminal care","volume":"43","author":"Frank","year":"1997","journal-title":"Can Fam Physician"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib4","series-title":"Palliative medicine","first-page":"1267","article-title":"Intestinal dysfunction and obstruction","author":"Mercadante","year":"2009"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib5","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jpainsymman.2007.04.011","article-title":"Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction","volume":"34","author":"Anthony","year":"2007","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib6","series-title":"Handbook of advanced cancer care","first-page":"465","article-title":"Treatment and prognosis","author":"Ripamonti","year":"2003"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jpainsymman.2014.09.013","article-title":"Double-Blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction","volume":"49","author":"Currow","year":"2015","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12957-015-0455-3","article-title":"Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer","volume":"13","author":"Peng","year":"2015","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib9","doi-asserted-by":"crossref","first-page":"7107","DOI":"10.7314\/APJCP.2013.14.12.7107","article-title":"Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer","volume":"14","author":"Kubota","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.dld.2005.10.010","article-title":"Randomised clinical trial investigating the effects of combined administration of octreotide and methylglucamine diatrizoate in the older persons with adhesive small bowel obstruction","volume":"38","author":"Zhang","year":"2006","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0959-8049(05)80012-7","article-title":"Palliation of malignant intestinal obstruction using octreotide","volume":"30A","author":"Khoo","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s11912-009-0040-4","article-title":"Surgical management of malignant bowel obstruction: strategies toward palliation of patients with advanced cancer","volume":"11","author":"DeBernardo","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpainsymman.2006.06.014","article-title":"Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review","volume":"33","author":"Mercadante","year":"2007","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/15360288.2015.1134748","article-title":"Medical management of pediatric malignant bowel obstruction in a patient with Burkitt's lymphoma and ataxia telangiectasia using continuous ambulatory drug delivery system","volume":"30","author":"Ghoshal","year":"2016","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1191\/026921698666334766","article-title":"Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction","volume":"12","author":"Hardy","year":"1998","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1191\/026921600669298725","article-title":"The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?","volume":"14","author":"Laval","year":"2000","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0885-3924(99)00147-5","article-title":"Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective, randomized trial","volume":"19","author":"Ripamonti","year":"2000","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib18","first-page":"188","article-title":"Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction","volume":"8","author":"Mercadante","year":"2000","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1089\/jpm.2014.0176","article-title":"Nonopioid pharmacological management of malignant bowel obstruction: a New Zealand-wide survey","volume":"17","author":"Mittal","year":"2014","journal-title":"J\u00a0Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib20","unstructured":"NHS Scotland. Scottish palliative care guidelines: Bowel obstruction. Available at: http:\/\/www.palliativecareguidelines.scot.nhs.uk. Accessed March 25,\u00a02015."},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib21","unstructured":"Fraserhealth: Hospice palliative care program symptom guidelines: Malignant bowel obstruction. Available at: https:\/\/www.fraserhealth.ca\/media\/13FHSymptomGuidelinesMalignantBowelObstruction.pdf. Accessed March 25,\u00a02016."},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpainsymman.2013.08.022","article-title":"Recommendations for bowel obstruction with peritoneal carcinomatosis","volume":"48","author":"Laval","year":"2014","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib23","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amsu.2015.07.018","article-title":"Management of intestinal obstruction in advanced malignancy","volume":"4","author":"Ferguson","year":"2015","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib24","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3949\/ccjm.78a.10052","article-title":"Malignant bowel obstruction: individualized treatment near the end of life","volume":"78","author":"Soriano","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jpainsymman.2010.05.002","article-title":"Octreotide","volume":"40","author":"Murphy","year":"2010","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0960-894X(00)00034-2","article-title":"Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor ligands","volume":"10","author":"Allen","year":"2000","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008396","article-title":"Octreotide for inoperable malignant bowel obstruction","author":"Ma","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib28","first-page":"1187","article-title":"Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial","volume":"22","author":"Mystakidou","year":"2002","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib29","first-page":"223","article-title":"Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer","volume":"9","author":"Ripamonti","year":"2001","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib30","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib31","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib32","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","article-title":"Chapter 8: assessing risk of bias in included 11 studies","author":"Higgins","year":"2008"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib33","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1684\/bdc.2011.1535","article-title":"SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction","volume":"99","author":"Laval","year":"2012","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib34","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1200\/JCO.2011.40.5712","article-title":"Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Mariani","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.317.7167.1185","article-title":"The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials","volume":"317","author":"Kunz","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/0269216307080173","article-title":"How should we measure emesis in palliative care?","volume":"21","author":"Saxby","year":"2007","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib37","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2012.45.0536","article-title":"Palliative interventions in patients with peritoneal metastases and malignant bowel obstruction","volume":"30","author":"Bellavance","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib38","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpainsymman.2010.05.007","article-title":"Malignant bowel obstruction: natural history of a heterogeneous patient population followed prospectively over two years","volume":"41","author":"Chakraborty","year":"2011","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib39","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2012.48.4634","article-title":"Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis","volume":"31","author":"Zelek","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jpainsymman.2015.04.001","article-title":"Octreotide for malignant bowel obstruction: commentary on Currow et\u00a0al","volume":"49","author":"Mercadante","year":"2015","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib41","first-page":"2817","article-title":"Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital","volume":"21","author":"Hwang","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.anchir.2005.05.011","article-title":"Treatment of malignant intestinal obstruction. A prospective study over 80 cases [French]","volume":"130","author":"Arvieux","year":"2005","journal-title":"Ann de Chirurgie"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib43","first-page":"1337","article-title":"Role of octreotide in the management of malignant intestinal obstruction [French]","volume":"55","author":"Barrelet","year":"1997","journal-title":"Medecine Hyg"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib44","first-page":"viii254","article-title":"Efficacy of octreotide acetate for malignant gastrointestinal obstruction","volume":"19","author":"Hisanaga","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib45","first-page":"596","article-title":"A\u00a0prospective evaluation of octreotide in the palliation of gastrointestinal symptoms","volume":"28","author":"Kilonzo","year":"2014","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib46","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jjco\/hyn035","article-title":"Clinical efficacy and safety of octreotide (SMS201-995) in terminally Ill Japanese cancer patients with malignant bowel obstruction","volume":"38","author":"Shima","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib47","first-page":"1991","article-title":"Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients","volume":"37","author":"Tanimura","year":"2010","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib48","first-page":"255","article-title":"Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage","volume":"38","author":"Uchino","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib49","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/IGC.0b013e318244ce93","article-title":"A\u00a0prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer","volume":"22","author":"Watari","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib50","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/026921639300700406","article-title":"Octreotide in relieving gastrointestinal symptoms due to bowel obstruction","volume":"7","author":"Mercadante","year":"1993","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib51","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/ijgc-00009577-200509000-00019","article-title":"Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis","volume":"15","author":"Mangili","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib52","first-page":"190","article-title":"Bowel obstruction in home-care cancer patients: four years experience","volume":"3","author":"Mercadante","year":"1995","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib53","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1006\/gyno.1996.0154","article-title":"Octreotide in the management of bowel obstruction in terminal ovarian cancer","volume":"61","author":"Mangili","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jpainsymman.2004.01.007","article-title":"Aggressive pharmacological treatment for reversing bowel obstruction","volume":"28","author":"Mercadante","year":"2004","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib55","first-page":"431","article-title":"Can malignant bowel obstruction in advanced cancer patients be treated at home?","volume":"19","author":"Porzio","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib56","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1049909108327967","article-title":"Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics","volume":"26","author":"Weber","year":"2009","journal-title":"Am J Hosp Palliat Care"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib57","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpainsymman.2005.05.018","article-title":"Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer","volume":"30","author":"Matulonis","year":"2005","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib58","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1191\/0269216306070751","article-title":"Sustained release octreotide may have a role in the treatment of malignant bowel obstruction","volume":"20","author":"Massacesi","year":"2006","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib59","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jpainsymman.2007.04.005","article-title":"The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research","volume":"34","author":"Krouse","year":"2007","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib60","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1177\/0269216311417036","article-title":"Designing and conducting randomized controlled trials in palliative care: a summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative","volume":"26","author":"Shelby-James","year":"2012","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib61","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpainsymman.2007.04.007","article-title":"Ethical issues in research to improve the management of malignant bowel obstruction: challenges and recommendations","volume":"34","author":"Laneader","year":"2007","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib62","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/SPC.0b013e3283597259","article-title":"Considerations in reporting palliative care clinical trials: standardizing information reported and authorship practices","volume":"6","author":"LeBlanc","year":"2012","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib63","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1191\/0269216304pm974ed","article-title":"Making the GRADE editorial","volume":"18","author":"Keeley","year":"2004","journal-title":"Palliat Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib64","series-title":"Follies and fallacies in medicine","first-page":"30","author":"Skrabanek","year":"1989"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib65","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib66","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1136\/bmj.e813","article-title":"Impact of single centre status on estimates of intervention effects in trials with continuous outcomes: meta-epidemiological study","volume":"344","author":"Bafeta","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib67","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/00005650-200106000-00010","article-title":"Multisite randomized controlled trials in health services research: scientific challenges and operational issues","volume":"39","author":"Weinberger","year":"2001","journal-title":"Med Care"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib68","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-134-8-200104170-00012","article-title":"The revised CONSORT statement for reporting randomized trials: explanation and elaboration","volume":"134","author":"Altman","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib69","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0197-2456(97)00145-1","article-title":"Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005\/ACTG 154 Trial Group","volume":"19","author":"Ch\u00eane","year":"1998","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jpainsymman.2016.05.032_bib70","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jclinepi.2015.12.003","article-title":"Missing data in randomized controlled trials testing palliative interventions pose a significant risk of bias and loss of power: a systematic review and meta-analyses","volume":"74","author":"Hussain","year":"2016","journal-title":"J\u00a0Clin Epidemiol"}],"container-title":["Journal of Pain and Symptom Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392416303244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0885392416303244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:18:27Z","timestamp":1760131107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0885392416303244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0885392416303244"],"URL":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.05.032","relation":{},"ISSN":["0885-3924"],"issn-type":[{"value":"0885-3924","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Somatostatin Analogues Compared With Placebo and Other Pharmacologic Agents in the Management of Symptoms of Inoperable Malignant Bowel Obstruction: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Journal of Pain and Symptom Management","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpainsymman.2016.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}